MedTrace Logo

SOLX Gold Shunt for Refractory Glaucoma

NCT01282346 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2017-02-23

No results posted yet for this study

Summary

To establish the clinical performance of the SOLX Gold Shunt for its ability to reduce intraocular pressure (IOP) in eyes with refractory glaucoma where medical and conventional surgical treatments have failed.

Conditions

Interventions

DEVICE

SOLX Gold Shunt

Single use implant

Sponsors & Collaborators

  • SOLX, Inc.

    lead INDUSTRY

Principal Investigators

  • Nilay Shah, MD · The Emmes Company, LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States
  • Brazil
  • Canada
  • Israel
  • Venezuela

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01282346 on ClinicalTrials.gov